The Influence of Dopamine Agonist Cabergoline on Oocyte Maturation
NCT ID: NCT01065376
Last Updated: 2011-07-21
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE4
120 participants
INTERVENTIONAL
2010-01-31
2011-07-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Effect of Cabergoline on Endometrial Vascularity During IntraCytoplasmic Sperm Injection
NCT02306564
Study of Cabergoline for Prevention of Ovarian Hyperstimulation Syndrome (OHSS) in In Vito Fertilization Cycles and Derivation of OHSS Biomarkers
NCT01535859
Clinical Study to Evaluate Efficacy of Cabergoline to Coasting in Reducing the Incidence of Ovarian Hyperstimulation Syndrome
NCT07043322
Antagonist Protocol in IVF
NCT02335736
Corifollitropin Alfa Application in PCOS Patients
NCT02215135
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
PURPOSE: To assess whether the timing cabergoline administration affects metaphase II oocytes numbers, embryo quality, pregnancy outcome and the incidence of OHSS.
METHODS: A prospective randomized study was designed to evaluate the possible of cabergoline affect on oocyte maturation. Women (n=120) under controlled ovarian hyperstimulation with the risk of OHSS (Estradiol(E2)\>4000 pg/ml, or \>18 follicle, \>11 mm development) randomized into two groups. Group I (n=60) received 0.5 mg oral cabergoline per day for 8 days on the day of hCG. Group II (n=60) received 0.5 mg oral cabergoline per day for 8 days on the day after oocyte retrieval immediately.
ANTICIPATED RESULTS: No significant differences were seen in the number of metaphase II oocytes, the embryo quality, the pregnancy rate and the incidence of OHSS.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
on the day of hCG
cabergoline administration for 8 days on the day of hCG.
the timing cabergoline administration
received 0.5 mg oral cabergoline per day for 8 days on the day of hCG
on the day after oocyte retrieval
cabergoline administration for 8 days on the day after oocyte retrieval
the timing cabergoline administration
received 0.5 mg oral cabergoline per day for 8 days on the day after oocyte retrieval
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
the timing cabergoline administration
received 0.5 mg oral cabergoline per day for 8 days on the day of hCG
the timing cabergoline administration
received 0.5 mg oral cabergoline per day for 8 days on the day after oocyte retrieval
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
20 Years
38 Years
FEMALE
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Shin Kong Wu Ho-Su Memorial Hospital
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Shin-Kong Wu Ho-Su Memorial Hospital
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Jiann-Loung Hwang, MD
Role: STUDY_CHAIR
Shin Kong Wu Ho-Su Memorial Hospital
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Department of Obstetrics and Gynecology, Shin-Kong Wu Ho-Su Memorial Hospital
Taipei, , Taiwan
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
SKH-8302-99-DR-28
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.